Daily Respiratory Research Analysis
Analyzed 319 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out today: a randomized human challenge trial showed that the RSV L‑protein inhibitor S‑337395 markedly lowered viral load and symptoms with favorable safety; a mechanistic study revealed that oxidized phosphatidylcholines blunt β2‑agonist bronchodilation via PKC‑dependent suppression of β2AR signaling; and a multicenter physiological study demonstrated that simple airway occlusions during NIV can accurately estimate inspiratory effort and lung stress at the bedside.
Research Themes
- Antiviral therapeutics for RSV
- Mechanisms of bronchodilator nonresponsiveness in asthma
- Bedside physiological monitoring during noninvasive ventilation
Selected Articles
1. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.
In a randomized, double-blind human challenge trial, once-daily S‑337395 significantly reduced RSV viral load AUC by 64.9% (30 mg) and 88.9% (300 mg) and lowered symptom AUC by 78.1% at 300 mg versus placebo. The drug was well tolerated without safety concerns and showed a clear dose-response.
Impact: This is one of the first randomized human challenge studies to show robust antiviral efficacy of an oral RSV polymerase inhibitor with symptom reduction, directly informing the therapeutic pipeline for a major respiratory pathogen.
Clinical Implications: If efficacy and safety are confirmed in field trials, an oral L-protein inhibitor could become an early outpatient therapy for RSV, potentially reducing viral shedding and symptom burden in high-risk adults and, ultimately, broader populations.
Key Findings
- Viral load AUC by qRT‑PCR was reduced by 64.87% at 30 mg and 88.94% at 300 mg versus placebo (both p<0.05).
- Culturable viral titers decreased by 72.32% (30 mg) and 86.17% (300 mg) compared with placebo.
- Total symptom score AUC fell by 78.15% in the 300 mg group (p<0.05), with good tolerability and no serious AEs.
Methodological Strengths
- Randomized, double-blind, placebo-controlled human challenge design with dose-ranging (1–300 mg).
- Dual virologic endpoints (qRT‑PCR viral load and viral culture) and standardized symptom assessments.
Limitations
- Human challenge in healthy adults may not reflect real‑world, high‑risk populations or severe disease.
- Efficacy assessed over short windows; larger outpatient trials are needed to confirm clinical benefit.
Future Directions: Proceed to multicenter outpatient RCTs in high-risk adults and pediatrics to evaluate time to recovery, transmission impact, and safety; explore resistance, PK/PD, and combination or sequencing with monoclonals.
BACKGROUND: S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model. METHODS: Healthy adults aged 18-55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2-12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set.
2. Oxidized Phosphatidylcholines Inhibit Airway Smooth Muscle β2-Adrenergic Receptors via Protein Kinase C.
Oxidized phosphatidylcholines, particularly OxPAPC, blunt β2‑agonist bronchodilation by raising isoproterenol EC50 ~4.3‑fold and lowering maximal relaxation, without affecting downstream adenylyl cyclase responses, indicating a receptor‑proximal defect. In human ASM, OxPAPC reduced cAMP generation (~50%) and PKA substrate VASP phosphorylation (~53%) via PKC; PKC inhibition rescued signaling and relaxation.
Impact: This study identifies a previously unrecognized PKC‑dependent mechanism by which oxidized lipids render β2‑agonists less effective, providing a mechanistic basis for bronchodilator insensitivity in inflamed airways.
Clinical Implications: Targeting PKC signaling or OxPC accumulation could restore β2‑agonist responsiveness in severe or oxidative stress–rich asthma phenotypes; biomarker‑guided strategies may identify patients with oxidized lipid signatures.
Key Findings
- OxPAPC pre‑exposure increased isoproterenol EC50 4.3‑fold and reduced maximal relaxation by 12.2% in MCh‑contracted murine trachea.
- OxPAPC did not blunt forskolin‑mediated relaxation, implicating a receptor‑proximal defect upstream of adenylyl cyclase.
- In human ASM, OxPAPC reduced Iso‑elicited cAMP by ~50% and PKA substrate VASP phosphorylation by up to 53%; PKC inhibition restored signaling and bronchodilation.
Methodological Strengths
- Convergent evidence across ex vivo tracheal rings, precision‑cut lung slices, in vivo murine studies, and human ASM cells.
- Pharmacologic dissection showing PKC dependency and receptor‑proximal specificity (no effect on forskolin/AC).
Limitations
- Mechanistic work primarily in animal tissues and cells; direct confirmation in human asthma in vivo is needed.
- OxPC species and in vivo concentrations in distinct asthma phenotypes require clinical validation.
Future Directions: Validate OxPC/PKC signatures in patients with β2‑agonist nonresponse; test PKC modulators or lipid‑targeted therapies to restore bronchodilation; develop diagnostic assays for oxidized lipid burden.
Understanding mechanisms for β2 adrenergic receptor (β2AR) insensitivity in asthmatics is incomplete. We discovered that the accumulation of oxidized phosphatidylcholines (OxPC) in the lung correlates with airway hyperresponsiveness, and OxPC induce contraction and cytokine synthesis in human airway smooth muscle (ASM) cells. Here, we test whether OxPC impair β2AR agonist bronchodilator responses and related mechanism(s) for β2AR insensitivity. Using tracheal rings from BALB/c mice, we assayed the effects of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) on β2AR agonist (isoproterenol (Iso))-induced relaxation of methacholine (MCh)-contracted airways. OxPAPC pre-exposure attenuated Iso-induced airway relaxation, increasing Iso EC50 4.3-fold and reducing maximum relaxation by 12.2%. OxPAPC did not affect adenylyl cyclase (AC) mediated relaxation induced by forskolin.
3. Airway Occlusions to Measure Inspiratory Effort, Respiratory Drive, and Lung Mechanics During Noninvasive Ventilation.
In 60 hypoxemic patients, Pocc was measurable in all, with mask‑specific conversion factors (K≈0.71 oro‑nasal; 0.80 full‑face). Pocc‑derived estimates of ΔPes and ΔPL,dyn closely matched esophageal references and accurately identified high inspiratory effort (AUC ~0.97–0.98), whereas ventilator P0.1 and plateau pressure were less reliable. Higher predicted effort and lung stress correlated with re‑intubation.
Impact: This pragmatic, multicenter physiological study provides a simple, generalizable bedside method to quantify inspiratory effort and lung stress during NIV without esophageal balloons, improving monitoring and risk stratification.
Clinical Implications: Clinicians can use brief occlusions to titrate support and detect injurious drive/effort during NIV; reliance on P0.1 or plateau pressure alone may be misleading. Values may inform escalation, weaning, and the need for sedation or extracorporeal support.
Key Findings
- Pocc measurable in 100% of patients; mask‑specific K factors (oro‑nasal 0.71; full‑face 0.80) enabled accurate ΔPes prediction.
- Pocc‑derived ΔPes identified high inspiratory effort (≤−10 cmH2O) with AUC 0.98 (oro‑nasal) and 0.97 (full‑face).
- Ventilator‑derived P0.1 poorly quantified drive; plateau pressure was unstable in most patients; higher predicted ΔPes/ΔPL,dyn and lower compliance associated with re‑intubation.
Methodological Strengths
- Multicenter prospective design with randomized mask order and esophageal manometry as reference standard.
- Strong diagnostic performance metrics (ROC, calibration) and clinically relevant associations with outcomes.
Limitations
- Post‑extubation hypoxemic cohort; generalizability to de novo NIV or COPD/hypercapnic failure requires validation.
- Short monitoring windows; no interventional titration protocol tested.
Future Directions: Prospective trials to evaluate Pocc‑guided NIV titration on clinical outcomes; validation in COPD, de novo NIV, and high‑drive ARDS; integration into ventilator software/alerts.
RATIONALE: In intubated patients, occlusion maneuvers allow non-invasive assessment of inspiratory effort, respiratory drive and lung mechanics. OBJECTIVES: To assess the feasibility of occlusion maneuvers during noninvasive ventilation (NIV). METHODS: In this multicenter study, 60 hypoxemic patients underwent two randomized 1-hour NIV sessions with oro-nasal and full-face masks after extubation. End-expiratory and end-inspiratory occlusions measured expiratory occlusion pressure (Pocc), 100-ms airway-pressure drop (P0.1), and plateau pressure. Esophageal manometry, calibrated before extubation, provided reference values for inspiratory effort, assessed as esophageal pressure swing (ΔPes), and dynamic transpulmonary driving pressure (ΔPL,dyn = pressure support - ΔPes).